Mabwell (Shanghai) Bioscience Co., Ltd.

Quick facts

Phase 3 pipeline

• 9MW0311 · Oncology
  9MW0311 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
• 9MW0813 · Oncology
  9MW0813 is a monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.
• 9MW2821 · Oncology
  9MW2821 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
• MW031 · Oncology
  MW031 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
• MW032 · Oncology
  MW032 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.

Phase 2 pipeline

• 6MW3211 · Oncology
  6MW3211 is a monoclonal antibody targeting PD-1.
• MW02
• MW05

Phase 1 pipeline

• 7MW3711
• 7MW4911
• 9MW2921
• 9MW3011
• 9MW3811 injection
• Experimental drug 9MW1911
• Other anti-cancer therapy

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Mabwell (Shanghai) Bioscience Co., Ltd. portfolio CI brief
• Mabwell (Shanghai) Bioscience Co., Ltd. pipeline updates RSS